Protection against tauopathy by the drug candidates NAP (Davunetide) and D-SAL: Biochemical, cellular and behavioral aspects

Current Pharmaceutical Design

Volumn 17, Issue 25, 2011, Pages 2603-2612

  Shiryaev, Natalia ^a,b   Pikman, Regina ^a,b   Giladi, Eliezer ^a,b   Gozes, Illana ^a,b  

^a The Adams Super Center for Brain Studies   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

Adnp; D sal; Microarray analysis; Mixed neuro glial cultures; Odor habituation dishabituation; Social recognition; Tau hyperphosphorylation

Indexed keywords

AL 309; AMYLOID BETA PROTEIN; DAVUNETIDE; PEPTIDE DERIVATIVE; TAU PROTEIN; UNCLASSIFIED DRUG;

ANIMAL BEHAVIOR; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; DRUG ACTIVITY; DRUG MECHANISM; HAPLOINSUFFICIENCY; IMMUNOCYTOCHEMISTRY; MALE; MOUSE; NERVE CELL CULTURE; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RAT; TAUOPATHY;

EID: 79958124972     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161211797416093     Document Type: Article

References (90)

1. Gozes I, Brenneman DE. A new concept in the pharmacology of neuroprotection. J Mol Neurosci 2000; 14: 61-8.
2. Furman S, Steingart RA, Mandel S, Hauser JM, Brenneman DE, Gozes I. Subcellular localization and secretion of activitydependent neuroprotective protein in astrocytes. Neuron Glia Biology 2004; 1: 193-9.
3. Brenneman DE, Gozes I. A femtomolar-acting neuroprotective peptide. J Clin Invest 1996; 97: 2299-307.
4. Gozes I, Brenneman DE. Activity-dependent neurotrophic factor (ADNF). An extracellular neuroprotective chaperonin? J Mol Neurosci 1996; 7: 235-44.
5. Gozes I, Vulih I, Spivak-Pohis I, Furman S. Neuroendocrine aspects of molecular chaperones: ADNF and ADNP. In: Henderson B, Pockley G, editors. Molecular Chaperones and Cell Signalling: Cambridge University Press, 2005: 251-62.
6. Brenneman DE, Hauser J, Neale E, et al. Activity-dependent neurotrophic factor: structure-activity relationships of femtomolaracting peptides. J Pharmacol Exp Ther 1998; 285: 619-27.
7. Guo Q, Sebastian L, Sopher BL, et al. Neurotrophic factors [activity-dependent neurotrophic factor (ADNF) and basic fibroblast growth factor (bFGF)] interrupt excitotoxic neurodegenerative cascades promoted by a PS1 mutation. Proc Natl Acad Sci USA 1999; 96: 4125-30.
8. Glazner GW, Boland A, Dresse AE, Brenneman DE, Gozes I, Mattson MP. Activity-dependent neurotrophic factor peptide (ADNF9) protects neurons against oxidative stress-induced death. J Neurochem 1999; 73: 2341-7.
9. Blondel O, Collin C, McCarran WJ, et al. A glia-derived signal regulating neuronal differentiation. J Neurosci 2000; 20: 8012-20.
10. Bassan M, Zamostiano R, Davidson A, et al. Complete sequence of a novel protein containing a femtomolar-activity-dependent neuroprotective peptide. J Neurochem 1999; 72: 1283-93.
11. Glazner GW, Camandola S, Mattson MP. Nuclear factor-kappaB mediates the cell survival-promoting action of activity-dependent neurotrophic factor peptide-9. J Neurochem 2000; 75: 101-8.
12. White DM, Walker S, Brenneman DE, Gozes I. CREB contributes to the increased neurite outgrowth of sensory neurons induced by vasoactive intestinal polypeptide and activity-dependent neurotrophic factor. Brain Res 2000; 868: 31-8.
13. Zamostiano R, Pinhasov A, Bassan M, et al. A femtomolar-acting neuroprotective peptide induces increased levels of heat shock protein 60 in rat cortical neurons: a potential neuroprotective mechanism. Neurosci Lett 1999; 264: 9-12.
14. Gressens P, Marret S, Bodenant C, Schwendimann L, Evrard P. Activity-dependent neurotrophic factor-14 requires protein kinase C and mitogen-associated protein kinase kinase activation to protect the developing mouse brain against excitotoxicity. J Mol Neurosci 1999; 13: 199-210.
15. Smith-Swintosky VL, Gozes I, Brenneman DE, D'Andrea MR, Plata-Salaman CR. Activity-Dependent Neurotrophic Factor-9 and NAP Promote Neurite Outgrowth in Rat Hippocampal and Cortical Cultures. J Mol Neurosci 2005; 25: 225-38.
16. Visochek L, Steingart RA, Vulih-Shultzman I, et al. PolyADP-ribosylation is involved in neurotrophic activity. J Neurosci 2005; 25: 7420-8.
17. Goldberg S, Visochek L, Giladi E, Gozes I, Cohen-Armon M. PolyADP-ribosylation is required for long-term memory formation in mammals. J Neurochem 2009; 111: 72-9.
18. Gozes I, Giladi E, Pinhasov A, Bardea A, Brenneman DE. Activity-dependent neurotrophic factor: intranasal administration of femtomolar-acting peptides improve performance in a water maze. J Pharmacol Exp Ther 2000; 293: 1091-8.
19. Gozes I, Davidson A, Gozes Y, et al. Antiserum to activitydependent neurotrophic factor produces neuronal cell death in CNS cultures: immunological and biological specificity. Brain Res Dev Brain Res 1997; 99: 167-75.
20. Steingart RA, Solomon B, Brenneman DE, Fridkin M, Gozes I. VIP and peptides related to activity-dependent neurotrophic factor protect PC12 cells against oxidative stress. J Mol Neurosci 2000; 15: 137-45.
21. Spong CY, Abebe DT, Gozes I, Brenneman DE, Hill JM. Prevention of fetal demise and growth restriction in a mouse model of fetal alcohol syndrome. J Pharmacol Exp Ther 2001; 297: 774-9.
22. Brenneman DE, Spong CY, Hauser JM, et al. Protective peptides that are orally active and mechanistically nonchiral. J Pharmacol Exp Ther 2004; 309: 1190-7.
23. Guo ZH, Mattson MP. Neurotrophic factors protect cortical synaptic terminals against amyloid and oxidative stress-induced impairment of glucose transport, glutamate transport and mitochondrial function. Cereb Cortex 2000; 10: 50-7.
24. Hashimoto Y, Kaneko Y, Tsukamoto E, et al. Molecular characterization of neurohybrid cell death induced by Alzheimer's amyloid-beta peptides via p75NTR/PLAIDD. J Neurochem 2004; 90: 549-58.
25. Ramirez SH, Sanchez JF, Dimitri CA, Gelbard HA, Dewhurst S, Maggirwar SB. Neurotrophins prevent HIV Tat-induced neuronal apoptosis via a nuclear factor-kappaB (NF-kappaB)-dependent mechanism. J Neurochem 2001; 78: 874-89.
26. Zheng G, Zhu K, Wei J, Jin Z, Duan M. Adeno-associated viral vector-mediated expression of NT4-ADNF-9 fusion gene protects against aminoglycoside-induced auditory hair cell loss in vitro. Acta Otolaryngol 2010.
27. Zhou FC, Fang Y, Goodlett C. Peptidergic agonists of activitydependent neurotrophic factor protect against prenatal alcoholinduced neural tube defects and serotonin neuron loss. Alcohol Clin Exp Res 2008; 32: 1361-71.
28. Kumral A, Yesilirmak DC, Sonmez U, et al. Neuroprotective effect of the peptides ADNF-9 and NAP on hypoxic-ischemic brain injury in neonatal rats. Brain Res 2006; 1115: 169-78.
29. Chiba T, Hashimoto Y, Tajima H, et al. Neuroprotective effect of activity-dependent neurotrophic factor against toxicity from familial amyotrophic lateral sclerosis-linked mutant SOD1 in vitro and in vivo. J Neurosci Res 2004; 78: 542-52.
30. Sari Y, Gozes I. Brain deficits associated with fetal alcohol exposure may be protected, in part, by peptides derived from activity-dependent neurotrophic factor and activity-dependent neuroprotective protein. Brain Res Rev 2006; 52: 107-18.
31. Steingart RA, Gozes I. Recombinant activity-dependent neuroprotective protein protects cells against oxidative stress. Mol Cell Endocrinol 2006; 252: 148-53.
32. Gozes I, Bardea A, Reshef A, et al. Neuroprotective strategy for Alzheimer disease: intranasal administration of a fatty neuropeptide. Proc Natl Acad Sci USA 1996; 93: 427-32.
33. Gozes I, Bachar M, Bardea A, et al. Protection against developmental retardation in apolipoprotein E-deficient mice by a fatty neuropeptide: implications for early treatment of Alzheimer's disease. J Neurobiol 1997; 33: 329-42.
34. Gressens P, Marret S, Hill JM, et al. Vasoactive intestinal peptide prevents excitotoxic cell death in the murine developing brain. J Clin Invest 1997; 100: 390-7.
35. Sigalov E, Fridkin M, Brenneman DE, Gozes I. VIP-Related protection against lodoacetate toxicity in pheochromocytoma (PC12) cells: a model for ischemic/hypoxic injury. J Mol Neurosci 2000; 15: 147-54.
36. Giladi E, Hill JM, Dresner E, Stack CM, Gozes I. Vasoactive intestinal peptide (VIP) regulates activity-dependent neuroprotective protein (ADNP) expression in vivo. J Mol Neurosci 2007; 33: 278-83.
37. Pinhasov A, Mandel S, Torchinsky A, et al. Activity-dependent neuroprotective protein: a novel gene essential for brain formation. Brain Res Dev Brain Res 2003; 144: 83-90.
38. Mandel S, Rechavi G, Gozes I. Activity-dependent neuroprotective protein (ADNP) differentially interacts with chromatin to regulate genes essential for embryogenesis. Dev Biol 2007; 303: 814-24.
39. Mandel S, Gozes I. Activity-dependent neuroprotective protein constitutes a novel element in the SWI/SNF chromatin remodeling complex. J Biol Chem 2007; 282: 34448-56.
40. Mandel S, Spivak-Pohis I, Gozes I. ADNP Differential Nucleus/Cytoplasm Localization in Neurons Suggests Multiple Roles in Neuronal Differentiation and Maintenance. J Mol Neurosci 2008; 35: 127-41.
41. Vulih-Shultzman I, Pinhasov A, Mandel S, et al. Activitydependent neuroprotective protein snippet NAP reduces tau hyperphosphorylation and enhances learning in a novel transgenic mouse model. J Pharmacol Exp Ther 2007; 323: 438-49.
42. Shiryaev N, Jouroukhin Y, Giladi E, Polyzoidou E, Grigoriadis NC, Rosenmann H, et al. NAP protects memory, increases soluble tau and reduces tau hyperphosphorylation in a tauopathy model. Neurobiol Dis 2009; 34: 381-8.
43. Matsuoka Y, Gray A, Hirata-Fukae C, et al. Intranasal NAP administration reduces accumulation of amyloid peptide and tau hyperphosphorylation in a transgenic mouse model of Alzheimer's disease at early pathological stage. J Mol Neurosci 2007; 31: 165-70.
44. Matsuoka Y, Jouroukhin Y, Gray AJ, et al. A neuronal microtubule-interacting agent, NAPVSIPQ, reduces tau pathology and enhances cognitive function in a mouse model of Alzheimer's disease. J Pharmacol Exp Ther 2008; 325: 146-53.
45. Gozes I. Neuroprotective peptide drug delivery and development: potential new therapeutics. Trends Neurosci 2001; 24: 700-5.
46. Gozes I, Morimoto BH, Tiong J, et al. NAP: research and development of a peptide derived from activity-dependent neuroprotective protein (ADNP). CNS Drug Rev 2005; 11: 353-68.
47. Gozes I. Activity-dependent neuroprotective protein: From gene to drug candidate. Pharmacol Ther 2007; 114: 146-54.
48. Gozes I, Stewart A, Morimoto B, Fox A, Sutherland K, Schmeche D. Addressing Alzheimer's disease tangles: from NAP to AL-108. Curr Alzheimer Res 2009; 6: 455-60.
49. Gozes I. Davunetide (NAP) Pharmacology: Neuroprotection and Tau. In: Martinez A, editor. Emerging Drugs and Targets for Alzheimer's Disease. 1st ed. Cambridge: Royal Society of Chemistry, 2010: 108-28.
50. Gozes I. Tau Pathology and Future Therapeutics. Curr Alzheimer Res 2010.
51. Sokolowska P, Passemard S, Mok A, Schwendimann L, Gozes I, Gressens P. Neuroprotective effects of NAP against excitotoxic brain damage in the newborn mice: Implications for cerebral palsy. Neuroscience 2010.
52. Gozes I. Microtubules, schizophrenia and cognitive behavior: Preclinical development of davunetide (NAP) as a peptide-drug candidate. Peptides 2010.
53. Gozes I. VIP-PACAP 2010: my own perspective on modulation of cognitive and emotional behavior. J Mol Neurosci 2010; 42: 261-3.
54. Dresner E, Agam G, Gozes I. Activity-dependent neuroprotective protein (ADNP) expression level is correlated with the expression of the sister protein ADNP2: Deregulation in schizophrenia. Eur Neuropsychopharmacol 2010.
55. Merenlender-Wagner A, Pikman R, Giladi E, Andrieux A, Gozes I. NAP (davunetide) enhances cognitive behavior in the STOP heterozygous mouse--a microtubule-deficient model of schizophrenia. Peptides 2010; 31: 1368-73.
56. Fernandez-Montesinos R, Torres M, Baglietto-Vargas D, et al. Activity-dependent neuroprotective protein (ADNP) expression in the amyloid precursor protein/presenilin 1 mouse model of Alzheimer's disease. J Mol Neurosci 2010; 41: 114-20.
57. Zemlyak I, Sapolsky R, Gozes I. NAP protects against cyaniderelated microtubule destruction. J Neural Transm 2009.
58. Zemlyak I, Sapolsky R, Gozes I. NAP protects against cytochrome c release: inhibition of the initiation of apoptosis. Eur J Pharmacol 2009; 618: 9-14.
59. Zemlyak I, Manley N, Vulih-Shultzman I, et al. The microtubule interacting drug candidate NAP protects against kainic acid toxicity in a rat model of epilepsy. J Neurochem 2009; 111: 1252-63.
60. Zemlyak I, Manley N, Sapolsky R, Gozes L. NAP protects hippocampal neurons against multiple toxins. Peptides 2007; 28: 2004-8.
61. Schmechel D, Gerard G, Vatakis NG, et al. A phase 2, doubleblind, placebo-controlled study to evaluate the safety, tolerability, and effect on cognitive function of AL-108 after 12 weeks of intranasal administration in subjects with mild cognitive impairment Alzheimer's & Dementia 2008; 4: T483.
62. Javitt DC. Effects of intranasal AL-108 (davunetide) on neurocognition and functional outcome in schizopherenia. Schizophrenia Research 2010; 117: 118-9.
63. Divinski I, Mittelman L, Gozes I. A femtomolar acting octapeptide interacts with tubulin and protects astrocytes against zinc intoxication. J Biol Chem 2004; 279: 28531-8.
64. Divinski I, Holtser-Cochav M, Vulih-Schultzman I, Steingart RA, Gozes I. Peptide neuroprotection through specific interaction with brain tubulin. J Neurochem 2006; 98: 973-84.
65. Holtser-Cochav M, Divinski I, Gozes I. Tubulin is the target binding site for NAP-related peptides: ADNF-9, D-NAP, and DSAL. J Mol Neurosci 2006; 28: 303-7.
66. Wilkemeyer MF, Chen SY, Menkari CE, Brenneman DE, Sulik KK, Charness ME. Differential effects of ethanol antagonism and neuroprotection in peptide fragment NAPVSIPQ prevention of ethanol-induced developmental toxicity. Proc Natl Acad Sci USA 2003; 100: 8543-8.
67. Gozes I, Divinski I, Piltzer I. NAP and D-SAL: neuroprotection against the beta amyloid peptide (1-42). BMC Neurosci 2008; 9 Suppl 3: S3.
68. Divinski I, Piltzer I, Gozes I. Primary Cell Cultures and Cell Lines. In: Gozes I, editor. Neuropeptide Techniques. Totowa, New Jersey: Humana Press, 2008: 21-6.
69. Pike CJ, Burdick D, Walencewicz AJ, Glabe CG, Cotman CW. Neurodegeneration induced by beta-amyloid peptides in vitro: the role of peptide assembly state. J Neurosci 1993; 13: 1676-87.
70. Lorenzo A, Yankner BA. Beta-amyloid neurotoxicity requires fibril formation and is inhibited by congo red. Proc Natl Acad Sci USA 1994; 91: 12243-7.
71. Genoud S, Lappe-Siefke C, Goebbels S, et al. Notch1 control of oligodendrocyte differentiation in the spinal cord. J Cell Biol 2002; 158: 709-18.
72. Shulga A, Thomas-Crusells J, Sigl T, et al. Posttraumatic GABA(A)-mediated [Ca2+]i increase is essential for the induction of brain-derived neurotrophic factor-dependent survival of mature central neurons. J Neurosci 2008; 28: 6996-7005.
73. Shinozaki Y, Sato Y, Koizumi S, Ohno Y, Nagao T, Inoue K. Retinoic acids acting through retinoid receptors protect hippocampal neurons from oxygen-glucose deprivation-mediated cell death by inhibition of c-jun-N-terminal kinase and p38 mitogen-activated protein kinase. Neuroscience 2007; 147: 153-63.
74. Agholme L, Lindstrom T, Kagedal K, Marcusson J, Hallbeck M. An in vitro model for neuroscience: differentiation of SH-SY5Y cells into cells with morphological and biochemical characteristics of mature neurons. J Alzheimers Dis 2010; 20: 1069-82.
75. Collombet J-M, Masqueliez C, Four E, et al. Early reduction of NeuN antigenicity induced by soman poisoning in mice can be used to predict delayed neuronal degeneration in the hippocampus. Neuroscience Letters 2006; 398: 337-42.
76. Maximova OA, Murphy BR, Pletnev AG. High-throughput automated image analysis of neuroinflammation and neurodegeneration enables quantitative assessment of virus neurovirulence. Vaccine 2010.
77. Alcalay RN, Giladi E, Pick CG, Gozes I. Intranasal administration of NAP, a neuroprotective peptide, decreases anxiety-like behavior in aging mice in the elevated plus maze. Neurosci Lett 2004; 361: 128-31.
78. Shiryaev N, Jouroukhin Y, Gozes I. 3R tau expression modifies behavior in transgenic mice. J Neurosci Res 2010; 88: 2727-35.
79. Hill JM, Cuasay K, Abebe DT. Vasoactive intestinal peptide antagonist treatment during mouse embryogenesis impairs social behavior and cognitive function of adult male offspring. Exp Neurol 2007; 206: 101-13.
80. Gregg B, Thiessen DD. A simple method of olfactory discrimination of urines for the Mongolian gerbil, Meriones unguiculatus. Physiol Behav 1981; 26: 1133-6.
81. Wilson DA. Olfaction as a model system for the neurobiology of mammalian short-term habituation. Neurobiol Learn Mem 2009; 92: 199-205.
82. Luna-Munoz J, Chavez-Macias L, Garcia-Sierra F, Mena R. Earliest stages of tau conformational changes are related to the appearance of a sequence of specific phospho-dependent tau epitopes in Alzheimer's disease. J Alzheimers Dis 2007; 12: 365-75.
83. Lagreze WA, Pielen A, Steingart R, et al. The Peptides ADNF-9 and NAP Increase Survival and Neurite Outgrowth of Rat Retinal Ganglion Cells In Vitro. Invest Ophthalmol Vis Sci 2005; 46: 933-8.
84. Gozes I, Spivak-Pohis I. Neurotrophic Effects of the Peptide NAP: A Novel Neuroprotective Drug Candidate. Curr Alzheimer Res 2006; 3: 197-9.
85. Wilkemeyer MF, Menkari CE, Spong CY, Charness ME. Peptide antagonists of ethanol inhibition of l1-mediated cell-cell adhesion. J Pharmacol Exp Ther 2002; 303: 110-6.
86. Parnell SE, Chen SY, Charness ME, Hodge CW, Dehart DB, Sulik KK. Concurrent dietary administration of D-SAL and ethanol diminishes ethanol's teratogenesis. Alcohol Clin Exp Res 2007; 31: 2059-64.
87. Toso L, Endres M, Vink J, Abebe DT, Brenneman DE, Spong CY. Learning enhancement with neuropeptides. Am J Obstet Gynecol 2006; 194: 1153-8; discussion 8-9.
88. Vink J, Incerti M, Toso L, Roberson R, Abebe D, Spong CY. Prenatal NAP+SAL prevents developmental delay in a mouse model of Down syndrome through effects on N-methyl-D-aspartic acid and gamma-aminobutyric acid receptors. Am J Obstet Gynecol 2009; 200: 524 e1-4.
89. Rupp CI. Olfactory function and schizophrenia: an update. Curr Opin Psychiatry 2010; 23: 97-102.
90. Wang J, Eslinger PJ, Doty RL, et al. Olfactory deficit detected by fMRI in early Alzheimer's disease. Brain Res 2010.